Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients

By Siergiejko Zenon   ŚŚwiebocka Ewa   Smith Nicola   Peckitt Clare   Leo Jo   Peachey Guy   Maykut Robert  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2223-2228

Informa Healthcare

Access to resources Recommend Favorite

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden

By Dewilde S.   Turk F.   Tambour M.   Sandström T.  

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1765-1776

Informa Healthcare

Access to resources Recommend Favorite

Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma

By Grossman H.L.   Schlender Amory   Alperin Peter   Stanley Elizabeth L.   Zhang Jie  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2779-2793

Informa Healthcare

Access to resources Recommend Favorite

Anti-IgE Therapy with Omalizumab Decreases Endothelin-1 in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma

By  

Respiration, Vol. 80, Iss. 6, 2010-06 ,pp. : 534-542

Karger

Access to resources Recommend Favorite

Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma

By Milgrom Henry   Fowler-Taylor Angel   Vidaurre Carlos Fernandez   Jayawardene Sumedha  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 163-169

Informa Healthcare

Access to resources Recommend Favorite